Evommune Presents Late-Breaking Phase 2a Data for EVO301 in Atopic Dermatitis at EADV 2026
Evommune presented full Phase 2a proof-of-concept data for EVO301, its IL-18 binding protein fusion protein, in a late-breaking oral session at the EADV 2026 Congress in Vienna. In the 70-patient trial in adults with moderate-to-severe atopic dermatitis, EVO301 reduced eczema severity (EASI) scores by 55% at Week 12, compared with 22% for placebo, with a favorable safety and tolerability profile.
Biomarker analyses showed modulation of the Th2 pathway as well as broad anti-inflammatory activity across the Th1 and Th17/22 pathways. Evommune anticipates starting a Phase 2b dose-ranging study in mid-2027.
